Selective androgen receptor modulators(SARMs)

Selective androgen receptor modulators(SARMs) is a novel class of androgen receptor ligands. They are intended to have the same kind of effects as androgenic drugs like anabolic steroids but be much more selective in their action. It may be used for many more clinical indications than the relatively limited legitimate uses that anabolic steroids are currently approved for.

1029692-15-6
LY-2452473
1029692-15-6
1612755-71-1
PF-06260414
1612755-71-1
TFM-4AS-1
188589-61-9

Background


An Overview of Selective androgen receptor modulators (SARMs)

Selective Androgen Receptor Modulators (SARMs) are a class of androgen receptor ligands that bind to androgen receptor and display tissue-selective activation of androgenic signaling. To date, most of the SARMs developed are non-steroidal and have the ability to activate androgen receptors in muscle and bone without accompanying activation or minimal activation of androgen receptors in the prostate or seminal vesicle.

Major types of SARMs

The role of SARMS is to regulate androgen receptors in the body. There are many SARMS, like MK-677, Andarine (S-4), LGD-4033, MK-2866, and Razadyne GW-501516 (Cardarine). MK-677 is a relatively early and mature SARMS, mainly used to increase the release of endogenous growth hormone to act on skeletal muscle growth. Andarine (S-4) is the most widely used SARMS by far. Its role in the muscle is mainly to significantly increase lean body mass, improve testosterone utilization, slow the degradation of the gonadal axis, and increase the rate of recovery of the gland axis. LGD-4033 can increase its own testosterone utilization rate and increase body fat content while increasing lean body mass. MK-2866 can increase the body's lean body mass and increase appetite. GW-501516 can reduce body fat, burn fat quickly and prevent muscle loss.

SARMs and diseases

SARM represents a new generation of tissue-selective androgen that has the potential to treat a variety of diseases that have not yet been achieved. SARM attempts to overcome the potential masculinization of steroids and androgens. Like men, women are also affected by sarcopenia, osteoporosis, and cachexia. Non-sustainable SARM can treat these diseases in women without the masculine side effects associated with steroidal androgens. Testosterone treatment has an effect in some female populations that exceed the risk of ambiguity and ambiguity in cardiovascular risk characteristics. Recent clinical studies have shown that while highlighting the ability of testosterone to improve sexual function and muscle mass in older men, it is confirmed that the heart risk of testosterone exceeds its therapeutic benefit.

References:

Ke, H. Z., Wang, X. N., O Malley, J., Lefker, B., & Thompson, D. D. (2005). Selective androgen receptor modulators-Prospects for emerging therapy in osteoporosis?. JOURNAL OF MUSCULOSKELETAL AND NEURONAL INTERACTIONS, 5(4), 355.